Chimeric PSGL-1 Protein Dimerization via Leucine Zipper
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant PSGL-1 proteins face challenges in achieving high expression levels and correct post-translational modifications, particularly in avoiding immune reactions and ensuring stability for diagnostic and therapeutic applications.
Innovation Solution
A recombinant chimeric PSGL-1 protein is developed using a leucine zipper domain for non-covalent dimerization, which allows for efficient expression and secretion in mammalian systems, avoiding the drawbacks of Fc domain usage, such as immune reactions and aggregation, and ensuring proper glycosylation and sulfation for selectin binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Fc domain is used for dimerization of PSGL-1, then expression levels improve, but immune reactions and aggregation occur
Solution Approach 1:
The patent extracts and removes the Fc domain from the chimeric protein structure, retaining only the essential PSGL-1 binding domain. This extraction eliminates the harmful immune reactions and aggregation associated with Fc domain while preserving the desired high expression levels and selectin binding functionality.
Solution Approach 2:
The patent introduces a linker peptide as an intermediary component between the PSGL-1 binding domain and the dimerization domain. This intermediary facilitates proper protein folding, stability, and dimerization while preventing the harmful effects of direct Fc domain association, thereby resolving the contradiction between expression efficiency and immune compatibility.
2Stability of the object's composition
If Fc domain is used for dimerization, then protein stability improves, but aggregation occurs
Solution Approach 1:
The patent extracts the dimerization function from the Fc domain and implements it through a dedicated dimerization domain (such as GCN4 leucine zipper). This separation maintains protein stability through proper dimerization while eliminating the aggregation-prone characteristics of the Fc domain.
Solution Approach 2:
The patent changes the structural parameters of the dimerization interface by using alternative dimerization domains with different physicochemical properties. These parameter changes maintain the necessary stability for protein function while avoiding the aggregation issues inherent in Fc domain-based dimerization.
3Ease of manufacture
If PSGL-1 is expressed in bacterial systems, then production cost decreases, but post-translational modifications are incorrect
Solution Approach 1:
The patent segments the PSGL-1 protein into modular domains (binding domain, linker, dimerization domain) that can be independently optimized. This segmentation allows expression in cost-effective bacterial systems for the core structure while enabling controlled addition of necessary post-translational modifications through eukaryotic expression systems or enzymatic treatment, thereby resolving the contradiction between production cost and modification accuracy.
Data Source
AI summary
The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer.In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein.The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.